{"entity":{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","aka":[],"tldr":"Payers would promise in advance to buy a set number of doses at a set price for any drug that meets a defined bar in a rare or childhood cancer, so companies know the market exists before they invest.","summary":"Modelled on Gavi's pneumococcal advance market commitment, a consortium of national payers and foundations pledges a guaranteed purchase (volume times price, for example $300 million over ten years) for the first therapy meeting a target product profile in a specified rare or paediatric indication: diffuse midline glioma, relapsed neuroblastoma, Ewing sarcoma, rare fusion-driven cancers. In exchange, the developer accepts a long-run affordable price and supply commitments. The commitment is only paid on delivery of a product that meets pre-registered efficacy criteria, so payers bear no risk of failure.","asOf":"2026-09-08","links":[{"label":"Gavi pneumococcal Advance Market Commitment","url":"https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc"}],"tags":[],"related":["idea-fund-paediatric-deferral-escrow","idea-fund-nonprofit-pharma"],"cancers":["neuroblastoma","sarcoma","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An AMC of a few hundred million dollars for a named paediatric indication brings at least two registration-intent programmes into that indication within five years where there were none, and shortens time from adult approval to paediatric labelling for eligible mechanisms.","rationale":"The pneumococcal AMC accelerated vaccine availability in poor countries by years and drew in new manufacturers. Paediatric oncology drug development is delayed by uncertain and small markets; the RACE Act mandates studies but does not make them profitable. A guaranteed market is the missing pull.","test":"Design one AMC with a target product profile and escrowed funds for a single indication, publish it, and count programme entries and phase 1/2 starts in that indication over five years against comparable indications.","maturity":"speculative","actor":"payer","cost":"large","horizonYears":6},"route":"/ideas/idea-fund-amc-paediatric-rare/","neighbours":{"idea":[{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/"},{"id":"idea-fund-paediatric-deferral-escrow","kind":"idea","name":"Escrow a share of adult revenue until the paediatric study is done","route":"/ideas/idea-fund-paediatric-deferral-escrow/"},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/"}],"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"company":[{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}],"roadmap":[{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/"}]}}